Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? - Wikidata - awgldk - TriplyDB

Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon?

Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon?

http://www.wikidata.org/entity/Q44762700

about

Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology.The uses and limitations of whole-body magnetic resonance imaging.Molecular imaging in myeloma precursor disease.Integrated whole body MR/PET: where are we?MR imaging of therapy-induced changes of bone marrow.A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma.Diagnostic and Prognostic Implications of Spine Magnetic Resonance Imaging at Diagnosis in Patients with Multiple Myeloma.11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma MRI and (18)FDG-PET in the assessment of bone marrow infiltration of the spine in cancer patients.Differentiation of myeloma and metastatic cancer in the spine using dynamic contrast-enhanced MRI.Whole-body imaging of the musculoskeletal system: the value of MR imaging.The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma.The role of imaging techniques in the management of multiple myeloma.Multiple myeloma lesion detection with whole body CT versus radiographic skeletal survey.Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review.Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).Risk Stratification in Multiple Myeloma.Intravoxel incoherent motion imaging for assessment of bone marrow infiltration of monoclonal plasma cell diseases.Whole-body MRI and PET/CT in multiple myeloma patients during staging and after treatment: personal experience in a longitudinal study.Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma.Guidelines for the use of imaging in the management of patients with myeloma.Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance.Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology.Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation.[Focal lesions in whole-body MRI in multiple myeloma : Quantification of tumor mass and correlation with disease-related parameters and prognosis].[Radiological diagnostics of multiple myeloma].Clinical value of ¹¹C-methionine PET/CT in patients with plasma cell malignancy: comparison with ¹⁸F-FDG PET/CT.[Multiple myeloma: current recommendations for imaging].Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters.

P2860

Q33881446-83CB967C-AAE5-487E-B5C3-F5A2F7AE49C3 Q33931426-99B16499-472F-4C20-892C-8CC300F1F7EF Q34505016-1C3ED4D7-A65E-40E4-8A39-D9400E623E53 Q34975185-BC2510FB-00CB-4E43-8EA9-8C171D86418F Q35633828-1A0810A9-CB79-493C-9646-202CC314A2CA Q35669888-FAC13B9B-DF96-4331-AF9B-B8C6121E6605 Q35862304-68E7F896-D838-4090-9CFE-800ED30E0448 Q35880375-7F439584-5867-4A80-95AE-5DA11373C797 Q36421210-C8C29EDC-CFA0-4B05-9D8D-C275C27A70DB Q36751535-7712A10A-448F-4461-A3A2-CB2E90060990 Q36842459-4B6D73E8-0332-4C58-929D-933597F3BE00 Q37676265-806257A2-57E4-425F-AD9F-3598EB33B2E3 Q38033606-647BAE91-B2FB-4154-B201-80DEE6779A5B Q38081200-DAA26D63-D330-466F-95A3-FBFAF17ECCC3 Q38101587-A0E0F86D-AE36-497C-AA67-6DEF8CC3FC95 Q38202605-A1EFEEDE-B987-43FC-9966-0D0F60CF4DB2 Q38609472-FC04F24E-1992-4147-9B4F-D361212FE18B Q38736249-F5D6196C-BA94-4104-BCD8-DD6D0FCA68F8 Q43645989-8721509E-F64D-4A0F-AD14-73BAB54AB822 Q45929472-2B53EEFD-FFE7-4045-AA17-82C26CAAA5DB Q46640882-DDD7FB17-498F-4160-8B69-9F196536E759 Q47329918-D0CADF2A-2FE0-4CC8-AFEE-975209B49BA3 Q47745383-3DAD333D-EDC9-42A7-93AF-BE11F547EBAB Q48262403-0A60BA77-0B2D-479A-A7BE-1667C88B1D18 Q49752739-A4DBCF1B-6DE3-4E3F-AC1B-219215EA9B7F Q50110526-DF9EED7B-0362-4402-946F-BAF016319EB1 Q53063070-7E74D90D-4C77-466D-AD29-2DD88538C748 Q53123777-3187F99C-F188-42E7-AAF8-67C1F8C84E5A Q53169883-FD817B95-9CE4-4409-9368-762D9FFE5A1B Q53420246-A1A08309-8A7D-4178-9174-B5753C4ADE48

P2860

Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon?

http://www.wikidata.org/entity/Q44762700

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Magnetic resonance imaging as ...... ng system of Durie and Salmon?

@en

Magnetic resonance imaging as ...... ng system of Durie and Salmon?

@nl

type

label

Magnetic resonance imaging as ...... ng system of Durie and Salmon?

@en

Magnetic resonance imaging as ...... ng system of Durie and Salmon?

@nl

prefLabel

Magnetic resonance imaging as ...... ng system of Durie and Salmon?

@en

Magnetic resonance imaging as ...... ng system of Durie and Salmon?

@nl

P1433

Q44762700-DD662EFA-2F16-4A81-9591-A62C429FDA40

P1476

Q44762700-696F0C80-99E2-4E76-B3C5-0831C23A1929

P2093

Q44762700-1C0ED9D3-7891-48CA-B735-0EE66866955C

Q44762700-275FC191-9D14-4873-9DA3-BEF597207B9A

Q44762700-302CEC17-360D-4681-948D-F86485998623

Q44762700-42079686-8A95-4AE7-9828-F144785CD9AF

Q44762700-55A709C1-B22D-4C74-9DDD-7B800E534FFF

Q44762700-80C8E8F7-BBB8-484D-B485-3431DCEAB5BC

Q44762700-CDB59633-4AE7-4D8C-A7A7-D554CB33A19E

Q44762700-DCFCB5EE-F7CF-46B6-8E91-24C37BF69B7A

P2860

Q44762700-3E13EC81-F608-43CC-BAD8-1363149712EF

Q44762700-5438A16A-6F61-47AA-A7BB-C4D7B887C417

Q44762700-5543C9AF-FFC5-4977-B848-7F26D6DBC9D9

Q44762700-604FAF6F-22E3-420C-9615-732992C06705

Q44762700-6456C4C8-F3DF-493E-B529-F5FD3E0B3126

Q44762700-7D39575D-6320-41E8-AA08-0662792108E7

Q44762700-9AFF2877-B3DA-40F9-9A9A-3F4C9A37B7CA

Q44762700-A0EE06A7-8422-4F3E-AF45-DF07D4F8B8AD

Q44762700-CA9385D6-F089-4711-BDAE-D1573B313797

Q44762700-D95289A4-2FDA-497A-AF77-52F2B9DF41B0

P304

Q44762700-6755514D-CF8E-4991-A701-841621F1D02A

P31

Q44762700-D52524B2-C38C-49F5-8831-4500830E14FF

P356

Q44762700-12CB758E-3382-48F8-9E01-B5AE48BF4966

P407

Q44762700-CF236214-7369-4CDB-A83B-1D75374F47D7

P433

Q44762700-C15B729E-E0B5-468C-A4FA-23FF0C072647

P478

Q44762700-FF0D271C-DBCB-48BC-8C93-BBB0E1421438

P50

Q44762700-CD135A51-4E2F-4CB0-A1FC-7052D020EEE2

P577

Q44762700-DEF02A3F-F60A-4A01-B7B0-AFE03BE15B7D

P5875

Q44762700-23EFD6C5-43DD-420E-9224-828E8140B694

P698

Q44762700-7E44C4B7-DFA9-469A-A938-DC008B5839CD

P356

P1433

P1476

Magnetic resonance imaging as ...... ng system of Durie and Salmon?

@en

P2093

Andrea Baur

http://www.w3.org/2001/XMLSchema#string

Axel Stäbler

http://www.w3.org/2001/XMLSchema#string

Dorothea Nagel

http://www.w3.org/2001/XMLSchema#string

Erhard Hiller

http://www.w3.org/2001/XMLSchema#string

Fridleif Bachner

http://www.w3.org/2001/XMLSchema#string

Maximilian Reiser

http://www.w3.org/2001/XMLSchema#string

Reiner Bartl

http://www.w3.org/2001/XMLSchema#string

Rolf Lamerz

http://www.w3.org/2001/XMLSchema#string

P2860

Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey.

A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Multiple Myeloma. Diagnostic challenges and standard therapy.

High-dose therapy and innovative approaches to treatment of multiple myeloma.

Prognosis in myeloma.

Bisphosphonates in multiple myeloma: current status; future perspectives.

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.

Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis.

Stage III multiple myeloma: clinical and prognostic value of spinal bone marrow MR imaging.

Long-term prognostic value of serum beta 2 microglobulin in myelomatosis.

P304

1334-1345

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.10818

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P50

Clemens Wendtner

P577

2002-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227789722

http://www.w3.org/2001/XMLSchema#string

P698

12216103

http://www.w3.org/2001/XMLSchema#string